A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy

Figure 1 Tumor growth time with intraperitoneal chemotherapy alone vs heated intraperitoneal chemotherapy at 41. 5°C. Tumor growth is delayed in heated intraperitoneal chemotherapy.

Figure 2 Heat increases the penetration of intraperitoneal chemotherapy into tissues. Modified from reference[53].

Figure 3 HIIC with MMC. The area under the curve ratio of intraperitoneal concentration over plasma concentration times time of heated intraoperative intraperitoneal mitomycin C is approximately 30. HIIC: Heated intraoperative intraperitoneal chemotherapy.

Figure 4 Absorption of mitomycin C from a hyperthermic solution containing 2, 4 or 6 L of 1. 5% dextrose peritoneal dialysis solution. Cited form reference[27].

Figure 5 Pharmacokinetic profile of heated intraoperative intraperitoneal doxorubicin showing that the doxorubicin concentration in the tumor nodule is higher than that in the peritoneal fluid.

Figure 6 The area under the curve ratio of intraperitoneal concentration over plasma concentration times time of heated intraoperative intraperitoneal cisplatin is approximately 10.

Figure 7 Pharmackinetics of HIIC with melphalan. Pharmacokinetic profile of melphalan given intraperitoneally at 70 mg/m² in 3 L of 1.5% dextrose peritoneal dialysis solution at 42°C for 90 min. Pharmacokinetic studies showed that the drug concentration in the tumor nodules was approximately 30% of the intraperitoneal concentration and 10 times the plasma concentration.

Figure 8 Mean total drug remaining in peritoneal cavity at 23 h. Hypertonic carrier solutions maintain the artificial ascites and paclitaxel concentrations, during early postoperative intraperitoneal paclitaxel instillation. Cite from reference[45].